Hebei Mojin Biotechnology Co.,Ltd
Diamond Supplier Enterprise Certification
- Diamond
Supplier - 6th
years
Diamond Supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: 13231137666
Tel: 15028179902
Tel: 13383610321
Tel: +86 13288715578
Tel: 13288715308
Tel: +86 15028179772
Tel: +86 13315458396
Tel: 15103291926
Tel: 13315457394
Mobile: 13231137666
Tel: 13231137666
Fax:
Province/state: Hebei
City: shijiazhuang
Street: room 1401,A building,Enjoy city,shijiazhuang city,hebei province,China
MaxCard:
Ms.betty Ms.mayCAS NO.41340-25-4
comestic(1-25)Kilogramcomestic(25-100)Kilogram
Hebei Mojin Biotechnology Co., Ltd,Our business covers more than 30 countries, most of the big customers come from Europe, America and other countries in the world, we can guarantee the quality and price. In recent decades, with the efforts of all employees, we have established many cooperative companies in shandong, henan, guangdong and other places. Our corporate purpose is based on the market, enhance the strength, take the road of scientific and environmental sustainable development, relying on the country. Technology r & d center, increase the investment in r & d, based on the domestic market, expand the international market, manufacturing quality products, sincere service to the society, into a modern, ecological, scientific and technological enterprise world.
Adenosine triphosphate can be used in the disease caused by tissue injury and activity reduction of ecto enzyme , including heart failure, carditis, miocardial infarction, cerebral arteriosclersis, coronary sclerosis, progressive muscular atrophy , cerebral hemorrhage , chronic hepatitis, cirrhosis of liver and hearing handicap, etc.
Product Detailed
| Description | Vonoprazan fumarate (Takecab®), discovered and developed by Takeda and Otsuka, was approved by the PMDA of Japan in December 2014, and is indicated for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis. Vonoprazan fumarate has a novel mechanism of action called potassium-competitive acid blockers, which competitively inhibit the binding of potassium ions to H+, K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. Vonoprazan does not inhibit Na+, K+-ATPase activity even at concentrations 500 times higher than that of their IC50 values against gastric H+, K+-ATPase activity. Furthermore, the drug is unaffected by the gastric secretory state, unlike PPIs. |
Product picture
Packing &shipping&Payment
Shipping:by sea or by air
Payment:T/T,,moneygram
Packaging Details drum
Port:Tianjin
Lead Time :
| Quantity(Kilograms) | 1 - 10000 | >10000 |
| Est. Time(days) | 5 | To be negotiated |
Advantage
In stock